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Foot-and-mouth disease (FMD) is a highly contagious and economically devastating disease of cloven-hoofed
animals in the world. The disease can be effectively controlled by vaccination of susceptible animals with the
conventional inactivated vaccine. However, one major concern of the inactivated FMD virus (FMDV) vaccine is
that it does not allow serological discrimination between infected and vaccinated animals, and therefore interferes with
serologic surveillance and the epidemiology of disease. A marker vaccine has proven to be of great value in disease
eradication and control programs. In this study, we constructed a marker FMDV containing a deletion of residues 93 to
143 in the nonstructural protein 3A using a recently developed FMDV infectious cDNA clone. The marker virus, r-HN/
3A93–143, had similar growth kinetics as the wild type virus in culture cell and caused a symptomatic infection in pigs. Pigs
immunized with chemically inactivated marker vaccine were fully protected from the wild type virus challenge, and the
potency of this marker vaccine was 10 PD50 (50% pig protective dose) per dose, indicating it could be an efficacious
vaccine against FMDV. In addition, we developed a blocking ELISA targeted to the deleted epitope that could clearly
differentiate animals infected with the marker virus from those infected with the wild type virus. These results indicate
that a marker FMDV vaccine can be potentially developed by deleting an immunodominant epitope in NSP 3A.Introduction
Foot-and-mouth disease (FMD) is a highly contagious
disease of cloven-hoofed animals, including cattle, pigs,
goats, sheep, and other species of wild ruminants, that is
characterized by the appearance of vesicles on the feet
and mouth. In endemic countries, FMD causes severe
economic loss as a result of a decline in productivity,
costs of control measures, and international trade re-
strictions imposed on livestock and animal products,
making FMD the most economically important disease
of livestock worldwide. In the past, FMD outbreaks have
occurred in most areas of the world, with the exception
of Greenland, Iceland, New Zealand, and the smaller
islands of Oceania [1]. Currently, FMD virus (FMDV) is* Correspondence: lipinghua@caas.cn; yinhong@caas.cn; liuzaixin@caas.cn
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The causative agent, FMDV, belongs to the genus
Aphthovirus in the family Picornaviridae, and exists as
seven antigenically and genetically distinct serotypes: O,
A, C, Asia1, SAT-1, SAT-2, and SAT-3. The virus is a
non-enveloped particle of icosahedral symmetry contain-
ing a single-stranded, positive-sense RNA genome ap-
proximately 8.5 kb in length. The viral genome has a
single open reading frame (ORF) that is translated into a
polyprotein, which is processed by virus-encoding proteases
(L, 3C, and 2A) to yield four structural (1A, 1B, 1C, and
1D) and ten nonstructural proteins (NSP) (L, 2A, 2B, 2C,
3A, 3B1-3, 3C, and 3D), as well as some relatively stable
precursor proteins. Although the mature NSPs, as well as
some of their protein precursors are involved in viral RNA
replication, their exact role in the viral life cycle is still not
fully understood [2,3].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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on regular vaccination with whole–virus inactivated vac-
cines, slaughter of infected and in-contact animals, together
with limitation of movement of susceptible animals and
animal products. Although inactivated FMD vaccines have
been used for many years and proved quite effective in con-
trol of clinical diseases [4], vaccinated animals cannot be
serologically distinguished from those infected with the
wild type (WT) virus, which is very important in disease
control and eradication programs. To date, the application
of 3ABC NSP-based strategies for differentiating infected
from vaccinated animals (DIVA) have been successfully im-
plemented to identify infection in vaccinated populations,
but there is still some concern of asymptomatic virus car-
riers without positive reaction in NSP serological tests [5,6].
Of particular concern is the fact that some vaccine formula-
tions may have residual NSPs, which makes it difficult to
identify infection in repeatedly-vaccinated populations [7,8].
Therefore, there is an increased need for development of
improved vaccines with a DIVA property against FMDV.
A marker vaccine, also called the DIVA vaccine, en-
ables accurate serological differentiation between in-
fected and vaccinated animals in conjunction with a
companion serological test, and has proved extremely
useful in outbreak control and sera-surveillance of infec-
tious diseases. It has been shown that the vaccines with
DIVA properties have successfully been used to control
and eradicate some infectious animal diseases [9-11]. In
addition, extensive studies have also demonstrated that
the marker vaccines combined with accompanying diag-
nostic methods make serosurveillance of infectious dis-
eases possible in endemic areas where a vaccination
program has been or is being implemented [11-13]. In
the present study, we describe the generation of a
marker FMDV (r-HN/3A93–143) containing a deletion of
residues 93 to 143 (this region harbors an immunodomi-
nant B-cell epitope of residues 99 to 105) in 3A protein
using a recently developed FMDV full-length infectious
cDNA clone [14]. The marker virus exhibited similar
growth kinetics to WT virus in culture cell, and caused a
symptomatic infection in pigs. The marker vaccine pre-
pared from binary ethylenimine (BEI)-inactivated r-HN/
3A93–143 proved to be effective in protecting pigs from
the WT virus challenge. Furthermore, a developed block-
ing ELISA targeted to the deleted epitope could clearly
differentiate animals infected with the marker virus from
those infected with the WT virus.
Materials and methods
Cells, viruses and antibodies
BHK-21 and BSR/T7 cells [15] were propagated as de-
scribed previously [16]. BSR/T7 cells were used to recover
the recombinant virus and BHK-21 cells were used for ti-
tration, in vitro growth, and plaque assays.WT FMDV r-HN (referred to here only), derived from a
plasmid encoding the complete FMDV O/HN/CHA/93
genome (pOFS) [14], was passaged four times in BHK cells
to further experiments.
MAb 3A24 directed against AEKNPLE (residues 99–105)
epitope in NSP 3A of FMDV and MAb 3B4B1 directed
against GPYAGPMER (residues 1–9) epitope in NSP 3B2
were obtained from the Lanzhou Veterinary Research Insti-
tute (LVRI). The region “AEKNPLE” was proven to be an
immunodominant B-epitope in 3A protein by detecting the
ability of FMDV reference sera recognized this region using
a peptide ELISA in our lab (data not yet published). Fluor-
escein isothiocyanate (FITC)-conjugated goat anti-mouse
IgG antibody was purchased from Sigma.
Construction and rescue of the marker FMDV
A full-length infectious cDNA clone (pOFS) of the
FMDV O/HN/CHA/93 was used to engineer the tar-
geted deletion in 3A protein via an overlap extension
method as previously described [17]. Briefly, two flank-
ing fragments (fragment A and B) were PCR amplified
from pOFS by primer sets HN-1 F/3A93-143R and
3A93-143 F/HN-4R. After amplification of the flanking
regions, the two amplicons were mixed and subjected
to the overlapping extension PCR with external primer pair
HN-1 F/HN-4R. The overlapping genome fragment was
digested with Bgl II and Nru I, and then cloned between
the Bgl II and Nru I sites of pOFS to construct the final
mutant full-length clone. After construction, the PCR-
amplified region was sequenced for verification of the in-
troduced deletion. The primers used for construction of
the deletion mutant were listed in Table 1.
The Not I-linearized mutant construct was transfected
into BSR/T7 cells using Lipofectamine™ 2000 (Invitro-
gen, Carlsbad, CA, USA) as described previously [15].
After transfection, cells were monitored until a typical
cytopathic effect of FMDV became apparent. Virus re-
covered from the transfected supernatant was passaged
up to four times in BHK-21 cell monolayers, and the
complete viral genomes of the marker virus, designated
r-HN/3A93–143, as well as WT virus of passage 4 [16]
were confirmed by nucleotide sequencing. The virus
stocks collected at passage 4 were used for growth stud-
ies, plaque assays, animal experiments, and production
of inactivated vaccines. Virus titer was determined by
calculating the 50% tissue culture infectious dose per
mL (TCID50/mL).
Detection of progeny viral RNA
To analyze the stability of the deletion in 3A protein of
FMDV, the marker virus was further passaged for 9
rounds (p13) in BHK-21 cells, and total viral RNAs were
extracted from the supernatants of each passage using a
QIAamp Viral RNA Mini kit (Qiagen, Valencia, CA,
Table 1 Primers used for the construction of the mutant FMDV full-length cDNA clone with the targeted deletion in
NSP 3A
Primer Sequence(5′→ 3′) Usage
HN-1 F CAAGAAGTGATTGAGCGGGT Amplification of fragment A
3A93-143R GGTTGTTCCCTCCCGGGCACGTCATCCAGTGAGTCATCCA
3A93-143 F TGGATGACTCACTGGATGACGTGCCCGGGAGGGAACAACC Amplification of fragment B
HN-4R GTTCCCTTCTTCATTCTCGC
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step RT-PCR was performed with the HN-1 F/HN-4R
primer pair. The PCR products were then purified and
sequenced directly to confirm the presence of the tar-
geted deletion in the marker virus.
Analysis of growth of the marker FMDV
BHK-21 cell monolayers in 6-well plates were infected
either with r-HN or r-HN/3A93–143 at an multiplicity of
infection (MOI) of 1 and incubated at 37 °C in 5% CO2.
After 1 h adsorption, the inoculum was removed, and
cell monolayers were washed twice with serum-free min-
imal essential medium (MEM) to remove unattached vi-
ruses. After washing, 2 mL complete medium was
added, and the plates were further incubated at 37 °C.
The virus-infected supernatants were collected at differ-
ent time points (0, 4, 8, 12 and 24 h post-infection), and
the virus titer was determined by TCID50 as described
above. The marker virus and WT virus were character-
ized by plaque assay in BHK-21 cells. Plaques were visu-
alized under a gum tragacanth overlay stained at 48 h
post-infection as previously described [18].
Immunofluorescent assay
BHK-21 cells (2 × 105) grown on a six-well plate were ei-
ther mock infected or infected with r-HN or r-HN/
3A93–143 at an MOI of 1. After 6 h post-infection, the
cells were fixed with 4% paraformaldehyde for 20 min at
room temperature, permeabilized for 20 min with 0.5%
Triton X-100 in PBS, and blocked for 1 h with 10% bo-
vine serum albumin in PBS. Then, the cells were incu-
bated for 1 h with MAb 3A24 or 3B4B1, and then
stained with fluorescein isothiocyanate (FITC)-conju-
gated goat anti-mouse IgG antibody for another 1 h.
The cells were examined in an Olympus BX40 inverted
fluorescence microscope.
Western blot
The cell lysates from r-HN or r-HN/3A93–143 infected
BHK-21 cells were prepared and separated on a 15%
polyacrylamide gel. The resolved proteins were trans-
ferred to PVDF membranes by standard methods. Blots
were blocked for 1 h in 5% nonfat milk powder in PBS
(pH 7.4), and the membranes were reacted with MAb3A24 or 3B4B1. After reaction, the membranes were in-
cubated with horseradish peroxidase (HRP)-conjugated
goat anti-mouse IgG antibody. Visualization of detected
proteins was achieved using diaminobenzidine (DAB).Animal experiments
Animal experiments were performed under Biosafety
Level 3 conditions in the animal facilities at LVRI follow-
ing the protocol approved by the Review Board of LVRI,
Chinese Academy of Agricultural Sciences (Permission
number:SYXK-GAN-2004-0005). At the beginning of
the experiments, all animals were negative for FMDV-
specific antibodies. The animals were euthanized by
intravenous injection of sodium pentobarbital at the end
of all experiments.
FMDV O/HN/CHA/93 isolate contains a deletion of
residues 93 to 102 in 3A protein, which is responsible
for the virus’s inability to cause disease in cattle [16,19].
Therefore, in this study, we investigated the virulence of
the marker virus in swine. Briefly, six 3-month-old pigs
were divided into two groups (n = 3 per group), and each
group was kept in a separate room. Group 1 was inocu-
lated with the WT virus, and group 2 was inoculated
with the marker virus. Inoculation was performed in the
heel bulb, with each pig receiving approximately 106
TCID50 in a volume of 0.2 mL. All animals were moni-
tored daily for signs of FMD infection. Lesion scores
were scored as previously described [20]. Briefly, clinical
signs were based on affected sites that were clearly dis-
tinct from inoculation sites, and were scored using the
following criteria: mouth, nostril, or tongue lesion be-
yond inoculation site = 1; one or more lesions per foot =
1. The maximum score is 5. Blood samples were col-
lected from the inoculated animals on the following days
post-infection (dpi) 0, 1, 2, 3, 4, 5, and 7, and FMDV
RNA in blood were detected by rRT-PCR as previously
described [21]. Furthermore, serum samples collected at
7, 14, 21, and 28 dpi were tested for FMDV-specific anti-
bodies as previously described [22]. The antibodies to
NSP 3ABC were also detected at 28 dpi by an FMDV
NSP 3ABC-I-ELISA kit from LVRI [23]. Viral RNAs
were extracted from vesicle samples, reverse transcribed,
and sequenced.
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The r-HN/3A93–143 and r-HN vaccine antigens were har-
vested from supernatants and lysates of infected BHK-21
cell cultures (a total of 4 × 108 cells), and inactivated
with BEI for 24 h at 25 °C. The vaccine antigens were
concentrated by polyethylene glycol precipitation and
purified through 10-30% sucrose density gradients as
described previously [24]. Two vaccines were prepared
as water-in-oil-in-water emulsions with Montadine ISA
201 (Seppic, Paris, France). The antigen concentration
present in the experimental vaccines was then estimated
using a previously described method [24]. Ten FMD-
seronegative pigs (3 months of age) were randomly sepa-
rated into two groups of four animals each, and one
control group of two animals. Subsequent to an initial
acclimatization period, the pigs were vaccinated intra-
muscularly with 2 mL (2 μg per 2 mL) chemically inacti-
vated r-HN/3A93–143 and r-HN vaccine, respectively.
Control animals were inoculated with 2 mL MEM. Four-
weeks post-vaccination, all animals were rebled, and sera
were tested for the presence of FMDV specific antibodies
and 3ABC antibodies. At 28 days post-vaccination (dpv),
all pigs were challenged intramuscularly in the neck with
1000 ID50 (50% pig infectious doses) of the WT virus.
This challenge model of FMDV has been well developed
for the FMD vaccine potency test in LVRI [25], and also
has been used as a standard method for detecting po-
tency of all commercially inactivated vaccines for pigs in
China [26]. The animals were examined daily for fever
and clinical signs. On 21 days post-challenge, serum
samples obtained from all experimental pigs were tested
for the presence of antibodies to 3ABC.
Assessment of potency of the marker vaccine in swine
The potency of the marker vaccine was estimated in
vaccinated pigs. The protocol was similar to the cattle
potency test described by the OIE. A total of seventeen
3-month-old pigs were divided into four groups. Groups
1–3 (5 pigs each) were vaccinated intramuscularly with
1 dose (2 μg), 1/3 dose, and 1/9 dose of vaccine prepared
from BEI-inactivated r-HN/3A93–143 vaccine antigen, re-
spectively. Pigs in group 4 (2 pigs) were inoculated with
MEM. At 28 dpv, all pigs were challenged intramuscu-
larly in the neck with 1000 ID50 of the WT virus. The
animals were then observed daily for the appearance of
clinical signs of FMD infection. Control animals devel-
oped lesions on at least one foot, while protected ani-
mals did not show any clinical signs. The PD50 content
of the vaccine was calculated based on the Spearman-
Karber method.
Differentiation ELISA assay
Serum samples collected from the animals infected either
with r-HN or r-HN/3A93–143 at 28 dpi were examined forspecific antibody to the targeted epitope using a blocking
ELISA (bELISA) assay. Briefly, microplates (Costar 3590,
Corning, NY, USA) were coated with FMDV-specific 2C
polyclonal antibody produced in rabbits (100 μL/well)
at a concentration of 1 μg/mL diluted in carbonate-
bicarbonate buffer (pH 9.6), and incubated overnight at
4 °C. Prior to all steps, the plates were washed four times
with PBST. During each subsequent step, the plates were
incubated at 37 °C. Blocking buffer (PBS containing 1%
gelatin) was added at 100 μL/well, and plates were incu-
bated for 1 h at 37 °C. Purified FMDV 2C3AB protein
[27] diluted in PBS was added at 1 μg/mL (100 μL/well),
and the plates were incubated for 1 h at 37 °C. After in-
cubation, serum samples in a 1:5 dilution in blocking
buffer were added (100 μL/well), and incubated over-
night at room temperature. Then, a volume of 100 μL
of horseradish peroxidase (HRP)-conjugated FMDV
3A MAb (3A24) diluted in blocking buffer (1:200) was
added to each well, and the plates were incubated for
1 h at 37 °C. Finally, the plates were incubated at room
temperature for 10–15 min with TMB substrate (3, 3′,
5, 5′-tetramethylbenzidine), and stopped by the addition
of 0.3 M sulfuric acid. The optical density (OD) was deter-
mined at 450 nm on an automated ELISA plate reader.
The results were expressed as the percentage of inhibition
using mean OD values of test sera as well as known
FMDV-positive and -negative swine sera. The percent
inhibition (PI) of samples was calculated as follows:
PI = [(negative reference serum OD − test sample OD)/
negative reference serum OD] × 100. The samples were
considered positive if the PI values were greater than or
equal to 46%.Results
Generation of the marker FMDV
In order to introduce a negative marker into previously
constructed plasmid pOFS, the overlap extension PCR
was used to produce a targeted genome fragment. This
fragment was digested by the appropriate restriction en-
zymes, and then cloned into pOFS plasmid to generate a
modified FMDV full-length cDNA clone named pOFS/
3A93–143. Sequence analysis of the mutant construct re-
vealed that pOFS/3A93–143 contains the expected dele-
tion and no other amino acid changes. Infectious virus
was obtained by transfection of a linearized mutant full-
length plasmid into BSR/T7 cells. The entire genomes of
passage 4 of the marker virus and WT virus were se-
quenced to confirm that two viruses had no other muta-
tions except for the presence of targeted deletion in the
marker virus. The genetic stability of truncated-3A was
also examined by nucleotide sequence analysis, and the
results show that the engineered deletion in 3A was
retained after up to 13 serial passages in BHK-21 cells.
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To investigate the possible effect of 3A length on virus
growth, in vitro growth kinetics of the marker virus
and WT virus were determined in BHK-21 monolayers
at an MOI of 1. The single-step growth curves revealed
no significant differences between these viruses, and
they all reached the peak titers at 12 h post-infection
(Figure 1). Additionally, the marker virus produced a
plaque phenotype similar to that of the WT virus in
BHK-21 cells (data not shown). These results suggest
that the deletion of residues 93 to 143 in 3A does not
affect virus replication in BHK-21 cells.
To determine the antigenic properties and the size of the
3A protein, the r-HN or r-HN/3A93–143 -infected cells were
examined by an immunofluorescent assay (Figure 2) and
western blot analysis (Figure 3). As Figures 2 and 3 show,
the WT virus reacted with both MAb 3A24 and 3B4B1,
conversely, the marker virus reacted strongly with MAb
3B4B1, while completely lacking reactivity with MAb 3A24.
Failure of MAb 3A24 to react with the marker virus shows
that the deletion of residues 93 to 143 in 3A abolished the
ability of the marker FMDV to be recognized by MAb
3A24 but not by MAb 3B4B1. In addition, Figure 3 shows
that the mobility of all intermediates of the 3B protein (3B
is too small to be readily observed by standard SDS-PAGE)
of the marker virus was slightly faster than the correspond-
ing intermediates of the WT virus, also indicating the
marker virus is the right construction.
Assessment of pathogenicity of the marker FMDV in swine
To evaluate the effect of the deletion in the 3A protein on
the pathogenicity in pigs, we performed direct inoculationFigure 1 Growth curves of r-HN and r-HN/3A93–143 in BHK-21 cells.
BHK-21 cells were infected either with r-HN or r-HN/3A93–143 at an MOI
of 1. At 0, 4, 8, 12 and 24 h post-infection, cells and supernatants were
harvested and the virus titers were determined by TCID50/mL on BHK-21
cells. The values of the viral titers represent the average obtained from
triplicate experiments.of r-HN or r-HN/3A93–143 in pigs. After inoculation, all ani-
mals produced an acute and synchronous disease. Clinical
signs appeared by 2 to 4 dpi, and reached the maximum
clinical score by 3 to 5 dpi (Table 2). Fever appeared at 2 to
4 dpi, and lasted for 3 to 5 dpi. Viremia was detected at 24
hpi, and reached a peak at 2 or 3 dpi, and lasted for 2 to 5
dpi. However, animals inoculated with the WT virus pro-
duced more vesicles beyond the injected sites and induced
fever (Table 2) a day earlier than in the marker virus-
inoculated animals. These results indicate that the marker
virus can cause a symptomatic infection in pigs, but the
clinical signs induced by the marker virus were milder than
those induced by the WT virus. Tests on serum samples
collected from inoculated animals at 7, 14, 21 and 28 dpi
revealed that high FMDV-specific antibodies (≥ 1:128) were
detectable at 7 dpi (data not shown), and reached higher
levels at 14 dpi (≥ 512) (Table 2). All pigs developed anti-
bodies to 3ABC at 28 dpi (Table 2), demonstrating that the
viral replication occurred in inoculated animals. Further-
more, sequence analysis of each sample recovered from the
pigs revealed that causative viruses were consistent with the
inoculated viruses in their genome sequences, indicating
that the targeted deletion remained stable during mutant
virus growth in pigs.
Swine protection experiment
To test the protective potential of inactivated vaccines
prepared from the WT and marker viruses in swine, we
designed a swine vaccination and challenge study. As
shown in Table 3, all vaccinated pigs developed high and
similar levels of FMDV-specific antibodies at 28 dpv,
however, in contrast, the unvaccinated controls did not
produce detectable FMDV-specific antibody (Table 3).
After challenge, the two unvaccinated controls developed
fever and anorexia, followed by typical FMD lesions on feet,
however, the animals vaccinated with vaccines did not
show any clinical signs of FMD (Table 3), demonstrat-
ing that all animals vaccinated with the r-HN/3A93–143
and r-HN vaccines were completely protected from
challenge with the WT virus. None of the animals
employed in this study was positive for antibody to
3ABC at 28 dpv, however, the two unvaccinated con-
trols developed significant antibody response against
3ABC at 21 days post challenge (Table 3), demonstrat-
ing that only the unvaccinated controls had become in-
fected after challenge with the WT virus.
Potency of the marker vaccine in swine
The potency of marker vaccine was estimated in vacci-
nated pigs. As expected, the unvaccinted controls devel-
oped severe symptoms of FMD, including fever, anorexia
and vesicular lesions on the feet. In contrast, 13/15
vaccinated animals did not show any clinical signs of
FMD during the course of the experiment, whereas two
Figure 2 Analysis of the marker epitope expression of the recombinant FMDV by immunofluorescence. Confluent BHK-21 cells were either mock
infected or infected with r-HN or r-HN/3A93–143 at an MOI of 1, incubated for 6 h, fixed and probed with anti-3A or anti-3B MAb, followed by incubation with
fluorescein isothiocyanate (FITC)-conjugated secondary antibody. The cells were visualized under an Olympus BX40 fluorescence microscope. Magnification, ×10.
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dose of marker vaccine developed delayed and slight
FMD clinical signs compared with the unvaccinated
controls (Table 4), indicating that 13/15 animals vacci-
nated with different doses of marker vaccine were pro-
tected from challenge with the WT virus. According toFigure 3 Analysis of the marker epitope expression of the
recombinant FMDV by western blotting. BHK-21 cells were either
mock infected or infected with r-HN or r-HN/3A93–143 at an MOI of 1,
and incubated at 37 °C. Infected cell extracts were prepared at 12 h post-
infection. Proteins were separated on a 12% SDS-PAGE, blotted, and probed
with anti-3A or anti-3B MAb. Protein marker is indicated on the right.the Spearman-Karber method, the potency of negative
marker vaccine reached 10 PD50 per dose, indicating
that the marker virus is a potential vaccine candidate.
Differential antibody responses against 3A in animals
inoculated with negative marker virus
To determine whether animals inoculated with the WT
virus and marker virus developed antibody responses to
the epitope of “AEKNPLE” of 3A protein, sera obtained
from pre-inoculated (0 dpv) or convalescent-phase (28
dpv) animals were detected by a bELISA developed using
MAb 3A24. We observed that the sera from all pre-
inoculated pigs and pigs inoculated with the marker virus
showed little inhibition (IP < 25%) of MAb 3A24 binding
to 2C3AB protein at 28 dpi; in contrast, the sera from ani-
mals inoculated with the WT virus exhibited significant in-
hibition (IP > 70%) of MAb 3A24 binding at 28 dpi
(Figure 4). In other words, the pigs infected with this
marker virus did not develop a measurable antibody
against the targeted epitope, while the pigs inoculated with
the WT virus induced a high-level antibody to the corre-
sponding epitope at 28 dpi. This indicates that the deletion
of residues 93 to 143 in 3A abolished the binding ability of
MAb 3A24 to the truncated 3A protein. These serological
results show that a bELISA developed using MAb 3A24
allows for differentiation of animals infected with the
wild type virus from those inoculated with the marker virus.
Discussion
The use of marker vaccines have become very attractive
and even mandatory in campaigns aiming toward the
control or eradication of economically devastating ani-
mal diseases. To date, several marker vaccines including
DNA vaccines [28,29], subunit vaccines [30,31], peptide
vaccines [32,33] as well as genetically modified virus vac-
cines [34-36]) have been developed using various strategies.
Table 2 Responses of swine directly inoculated with r-HN or r-HN/3A93–143
Virus Piga Maximum viremia
titreb (dpi)





r-HN 2408 7.23 (2) Yes (2 and 3) 4/5 (3) 1:1024 (14) +
r-HN 2411 7.7 (2) Yes (2 to 5) 3/5 (4) 1:512 (14) +
r-HN 2412 6.9 (3) Yes (3 to 5) 4/5 (5) 1:720 (7) +
r-HN/3A93–143 2413 7.1 (2) Yes (3 to 5) 4/5 (4) 1:720 (14) +
r-HN/3A93–143 2421 6.0 (3) Yes (3 to 5) 2/5 (3) 1:512 (14) +
r-HN/3A93–143 2422 7.3 (3) Yes (4 to 5) 2/5 (5) 1:720 (7) +
aPigs were inoculated with 106 TCID50 of r-HN or r-HN/3A93–143 by intradermal route.
bValues are expressed as the log10 RNA copies/mL. Dpi here indicates the day(s) post-inoculation that the virus peak was detected.
cFever defined as rectal temperature > 40 °C. Dpi here indicates the days when fever was detected.
dClinical scores were scored as previously described [24]. The maximum score is 5. Dpi here indicates the day after inoculation that the maximum score
was reached.
eLPBE-antibody, liquid-phase blocking ELISA antibody. Dpi here indicates the day after inoculation that the maximum LPBE-antibodies were reached.
f3ABC antibody, the antibody to the nonstructural protein 3ABC of FMDV. Dpi here indicates four-weeks after inoculation that 3ABC antibodies were detected.
+, positive, −, negative.
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producing an antibody response that is different from the
antibody responses produced by the WT virus. However,
epidemiological and regulatory considerations suggested
that a DIVA vaccine should be developed by deletion of an
immunodominant epitope or certain viral protein to create
a negative marker [24,34,35]. Herpesvirus negative marker
vaccines were first developed in 1980, and their use has
contributed to disease control and eradication in some
countries [11,37,38]. Following the successes of these vac-
cines, negative marker vaccines of some animal diseases
have been developed by identifying and selecting non-
essential genes [35,39-42], and some of them have success-
fully been used to control disease outbreaks [9,10].
The studies of other viral negative marker vaccines pro-
vide insight into the development of a new marker vaccine











Negative controls 3509 no
3510 no
aBinary ethyleimine-inactivated antigen vaccine, 2 μg/2 mL in one dose.
bPigs were challenged by intramuscular inoculation of 1000 ID50 of r-HN.
cLPBE-antibody, liquid-phase blocking ELISA antibody. Dpi here indicates four-week
d3ABC antibody, the antibody to the nonstructural protein 3ABC of FMDV. Dpi here
+, positive, −, negative.was developed by deleting partial VP1 G–H loop [43], and
the subsequent result demonstrated that this FMD negative
marker vaccine can fully protect cattle from experimental
challenge and meet the DIVA purpose [35]. However, not
only the G-H loop of the VP1 protein, but also other anti-
genic sites of the capsid proteins are responsible for the
complete immunogenicity of the FMDV vaccine [44,45].
Therefore, it is recommended that the negative marker vac-
cine should be designed by deletion or modification of
some epitopes in NSPs [46]. More recently, FMDV marker
vaccines featuring the deletion of the leader protein have
been produced by modification or deletion of specific epi-
topes in NSP 3D and/or 3B [47]. These attenuated, antigen-
ically marked vaccines enable serological differentiation
infected from vaccinated animals in conjunction with a
companion diagnostic test. However, a major disadvantage
of live-attenuated vaccines is that the viruses were tooA93–143 chemically inactivated vaccines and r-HN











s after vaccination that LPBE-antibodies were detected.
indicates three-weeks after challenge that 3ABC antibodies were detected.
Table 4 The result of the PD50 test of the r-HN/3A93–143 vaccine
Vaccine dosea Pig Protectionb LPBE-antibodyc (dpi) 3ABC antibodyd (dpi)
1 1501 yes 1:512 –
1503 yes 1:256 –
1504 yes 1:128 –
1528 yes 1:64 –
1536 yes 1:256 –
1/3 1502 yes 1:128 –
1506 yes 1:32 –
1529 yes 1:256 –
1534 yes 1:64 –
1533 yes 1:256 –
1/9 1505 yes 1:64 –
1507 yes 1:128 –
1527 no < 1:6 +
1532 no < 1:6 +
1535 yes 1:512 –
control 026 no < 1:6 +
030 no < 1:6 +
a2 μg per dose of binary ethyleimine-inactivated antigen vaccine.
bPigs were challenged by intramuscular inoculation of 1000 ID50 of r-HN.
cLPBE-antibody, liquid-phase blocking ELISA antibody. Dpi here indicates four-weeks after vaccination that LPBE-antibodies were detected.
d3ABC antibody, the antibody to the nonstructural protein 3ABC of FMDV. dpi here indicates three-weeks after challenge that 3ABC antibodies were detected.
+, positive, −, negative.
Figure 4 bELISA. (A) Differential antibody response in animals infected with WT virus using MAb 3A24 raised against 3A. (B) Differential antibody
response in animals infected with the marker virus using MAb 3A24 raised against 3A. Samples were collected before inoculation and at 28 dpi.
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sponses against virus infection [48,49]. Owing to these
problems, an improved marker vaccine needs to be devel-
oped to assist FMD control.
Sequence alignment and our studies (data not yet pub-
lished) showed that the epitope of residues 99 to 105 of
the 3A protein is well-conserved and immunodominant
among different serotypes of FMDV. Previous reports
have shown that the FMDV 3A protein can tolerate some
deletions (residues 93 to 144, 91 to 104) without affecting
the replicating abilities in the BHK-21 cell [50,51]. More re-
cently, FMDV with a deletion of residues 87 to 106 in 3A
can also be recovered from full-length infectious cDNA
clones [52]. Although the viruses featuring these deletions
in 3A have been successfully rescued, the potential DIVA
capabilities of these viruses have not been investigated.
Therefore, in the present study, we constructed a marker
FMDV containing the deletion of residues 93 to 143 in the
3A protein. We observed that the marker virus had similar
growth kinetics and plaque morphology with the WT virus
in the BHK-21 cell and was genetically stable after 13 serial
passages in BHK-21 cells, indicating its potential advantages
for production of the vaccine against FMDV.
In this study, a negative marker was introduced into
FMDV by deletion of residues 93 to 143 in the 3A pro-
tein, which contains an immunodominant B-cell epitope
of residues 99 to 105 (AEKNPLE). The results of the im-
munofluorescent assay and western blot analysis showed
that MAb 3A24 had high reactivity with the WT virus,
but failed to react with the marker virus. Based on the
property of MAb 3A24, we developed a bELISA with
this MAb to detect differential antibody response in ani-
mals infected with the WT virus and marker virus. As
expected, pigs infected with this marker virus did not
develop a measurable antibody against the targeted epi-
tope by a developed blocking ELISA, but the pigs in-
fected with the wild type virus produced a high-level
antibody to the corresponding deleted epitope at 28 dpi,
demonstrating that a developed bELISA could clearly
differentiate animals infected with the WT virus from
those inoculated with the marker virus. Therefore, the
epitope “AEKNPLE” of 3A is a suitable target for the
development of negative marker vaccine with DIVA
capability.
Systematic vaccination programs with BEI-inactivated
whole virus antigen used in conjunction with oil adju-
vants have successfully reduced the number of FMD
outbreaks in the enzootic areas of the world. In the
current work, we compared the protective efficacy of the
vaccine made from BEI-inactivated r-HN/3A93–143 or
r-HN in pigs. The results demonstrate that a single vac-
cination with these vaccines protected all pigs from chal-
lenge with WT virus, and all vaccinated animals
developed high and similar levels of FMDV-specificantibodies compared with the unvaccinated controls, in-
dicating that the marker virus has good immunogenicity
as the WT virus. In addition, our study shows that the
potency of the marker vaccine could get 10 PD50 per
dose for pigs. In this study, animals vaccinated with a
single-dose r-HN/3A93–143 at 28 dpv did not produce a
significant antibody response to NSP 3ABC and the tar-
geted epitope (data not shown), in contrast, animals in-
fected with the marker virus all developed antibody
responses to NSP 3ABC that were unable to block the
binding of 3A MAb targeted against the marker epitope
at four weeks following inoculation. These results dem-
onstrate that this recombinant virus with a negative
marker is a potential marker vaccine candidate, enabling
serological discrimination between vaccinated and in-
fected animals utilizing developed blocking ELISA.
Taken together, our study indicates that the deletion of
the immunodominant epitope in the 3A protein of FMDV
can be potentially useful as a negative marker for the
development of the DIVA vaccine to help FMD control
and serosurveillance.
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